Scientific contributions
NeoGenomics is committed to the advancement of cancer care. We work with institutions and thought leaders to continually innovate and develop more impactful diagnostic, therapy selection, and MRD tests.
PTEN IHC CDx: Now Available for Prostate Carcinoma! Learn more
NeoGenomics is transitioning to a new billing system. Learn more
NeoGenomics is committed to the advancement of cancer care. We work with institutions and thought leaders to continually innovate and develop more impactful diagnostic, therapy selection, and MRD tests.